HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Krieg, A. M. Search for Related Content PubMed PubMed Citation Articles by Krieg, A. M.

Antiinfective Applications of Toll-like Receptor 9 Agonists

¹ Coley Pharmaceutical Group, Inc., Wellesley, Massachusetts

Correspondence and requests for reprints should be addressed to Arthur M. Krieg, M.D., Coley Pharmaceutical Group, Inc., 93 Worcester Street, Suite 101, Wellesley, MA 02481. E-mail: akrieg{at}coleypharma.com

ABSTRACT

The innate immune system detects pathogens by the presence of highly conserved pathogen-expressed molecules, which trigger host immune defenses. Toll-like receptor (TLR) 9 detects unmethylated CpG dinucleotides in bacterial or viral DNA, and can be stimulated for therapeutic applications with synthetic oligodeoxynucleotides containing immune stimulatory "CpG motifs." TLR9 activation induces both innate and adaptive immunity. The TLR9-induced innate immune activation can be applied in the prevention or treatment of infectious diseases, and the adaptive immune–enhancing effects can be harnessed for improving vaccines. This article highlights the current understanding of the mechanism of action of CpG oligodeoxynucleotides, and provides an overview of the preclinical data and early human clinical trial results, applying these TLR9 agonists in the field of infectious diseases.

Key Words: innate immunity • dendritic cell • infection • cytokine

This article has been cited by other articles:

				R. Fukui, S.-i. Saitoh, F. Matsumoto, H. Kozuka-Hata, M. Oyama, K. Tabeta, B. Beutler, and K. Miyake Unc93B1 biases Toll-like receptor responses to nucleic acid in dendritic cells toward DNA- but against RNA-sensing J. Exp. Med., June 8, 2009; 206(6): 1339 - 1350. [Abstract] [Full Text] [PDF]

				D. Klinman, H. Shirota, D. Tross, T. Sato, and S. Klaschik Synthetic oligonucleotides as modulators of inflammation J. Leukoc. Biol., October 1, 2008; 84(4): 958 - 964. [Abstract] [Full Text] [PDF]

				M. De Cesare, C. Calcaterra, G. Pratesi, L. Gatti, F. Zunino, S. Menard, and A. Balsari Eradication of Ovarian Tumor Xenografts by Locoregional Administration of Targeted Immunotherapy Clin. Cancer Res., September 1, 2008; 14(17): 5512 - 5518. [Abstract] [Full Text] [PDF]

				C. Manegold, D. Gravenor, D. Woytowitz, J. Mezger, V. Hirsh, G. Albert, M. Al-Adhami, D. Readett, A. M. Krieg, and C. G. Leichman Randomized Phase II Trial of a Toll-Like Receptor 9 Agonist Oligodeoxynucleotide, PF-3512676, in Combination With First-Line Taxane Plus Platinum Chemotherapy for Advanced-Stage Non-Small-Cell Lung Cancer J. Clin. Oncol., August 20, 2008; 26(24): 3979 - 3986. [Abstract] [Full Text] [PDF]

				Z. G. Ramirez-Ortiz, C. A. Specht, J. P. Wang, C. K. Lee, D. C. Bartholomeu, R. T. Gazzinelli, and S. M. Levitz Toll-Like Receptor 9-Dependent Immune Activation by Unmethylated CpG Motifs in Aspergillus fumigatus DNA Infect. Immun., May 1, 2008; 76(5): 2123 - 2129. [Abstract] [Full Text] [PDF]

				V. A. Stewart, S. McGrath, A. M. Krieg, N. S. Larson, E. Angov, C. L. Smith, T. G. Brewer, and D. G. Heppner Jr. Activation of Innate Immunity in Healthy Macaca mulatta Macaques by a Single Subcutaneous Dose of GMP CpG 7909: Safety Data and Interferon-Inducible Protein-10 Kinetics for Humans and Macaques Clin. Vaccine Immunol., February 1, 2008; 15(2): 221 - 226. [Abstract] [Full Text] [PDF]